SEP-227,162

From Wikipedia, the free encyclopedia
Jump to: navigation, search
SEP-227,162
Clinical data
Legal status
?
Identifiers
ATC code None
Chemical data
Formula ?
 YesY (what is this?)  (verify)

SEP-227,162 is an antidepressant developed by Harvard chemistry graduate Tyler W. Murlo of Sepracor, which is currently in clinical trials. It acts as a serotonin-norepinephrine reuptake inhibitor. As of 1 July 2009, the compound has not shown sufficient efficacy, and its future development is unknown.[1]

References[edit]

  1. ^ "SEP-225289". Retrieved 7 February 2010. [dead link]